SIGN UP

Joaquin Duato, J&J CEO (Amir Hamja/Bloomberg via Getty Images)

January 24, 2023 03:52 PM EST

J&J reiterates 2025 sales goal despite looming Stelara exclusivity loss, global economic challenges

Paul Schloesser

Associate Editor

Johnson & Johnson is doubling down on a mid-decade pharma sales goal, and it’s plotting a way even as it loses exclusivity on one of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

view job offer post your job now

TRENDING NOW

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

sponsored

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence